{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:58:34Z","timestamp":1790686714048,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016190","name":"Trond Mohn stiftelse","doi-asserted-by":"publisher","award":["BFS2017TMT01"],"award-info":[{"award-number":["BFS2017TMT01"]}],"id":[{"id":"10.13039\/100016190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["288164"],"award-info":[{"award-number":["288164"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KLINBEFORSK","award":["2019202"],"award-info":[{"award-number":["2019202"]}]},{"DOI":"10.13039\/501100010586","name":"Haukeland\u00a0Universitetssjukehus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010586","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Bergen","id":[{"id":"https:\/\/ror.org\/03zga2b32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01692-8","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:00:49Z","timestamp":1787914849000},"page":"1541-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct04578639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06663111","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7475-1147","authenticated-orcid":false,"given":"Trond Tr\u00e6tteberg","family":"Serkland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Kristina Fredheim","family":"Oma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik I.","family":"Hallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias H.","family":"\u00d8ver\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Owren","family":"Nygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"R\u00f6blitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"8","key":"1692_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765\u201379.","journal-title":"JAMA"},{"issue":"10422","key":"1692_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202.","journal-title":"Lancet"},{"issue":"3","key":"1692_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41582-023-00775-5","volume":"19","author":"K Bjornevik","year":"2023","unstructured":"Bjornevik K, Munz C, Cohen JI, Ascherio A. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160\u201371.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1692_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.410430409","volume":"43","author":"MK Storch","year":"1998","unstructured":"Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol. 1998;43(4):465\u201371.","journal-title":"Ann Neurol"},{"issue":"2","key":"1692_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/5532","volume":"5","author":"CP Genain","year":"1999","unstructured":"Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med. 1999;5(2):170\u20135.","journal-title":"Nat Med"},{"issue":"310","key":"1692_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab4176","volume":"7","author":"R Li","year":"2015","unstructured":"Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1692_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"8","key":"1692_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1352458517713668","volume":"24","author":"T Spelman","year":"2018","unstructured":"Spelman T, Frisell T, Piehl F, Hillert J. Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2018;24(8):1087\u201395.","journal-title":"Mult Scler"},{"issue":"3","key":"1692_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14712598.2019.1568407","volume":"19","author":"KM Myhr","year":"2019","unstructured":"Myhr KM, Torkildsen O, Lossius A, Bo L, Holmoy T. B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther. 2019;19(3):261\u201371.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"1692_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, Fox EJ, Cohen JA. Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs. 2021;35(9):985\u201397.","journal-title":"CNS Drugs"},{"issue":"8","key":"1692_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21(8):693\u2013703.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1692_CR12","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1093\/brain\/awaf170","volume":"148","author":"G Giovannoni","year":"2025","unstructured":"Giovannoni G, James L, Adeniran AA, Gold J, Young LS, Selwood DL, et al. The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Brain. 2025;148(9):3057\u201371.","journal-title":"Brain"},{"issue":"2","key":"1692_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200094","volume":"10","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Bar-Or A, Weber MS, Kletzl H, Gunther A, Manfrini M, et al. Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200094.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"1692_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ana.26534","volume":"93","author":"ZLE van Kempen","year":"2023","unstructured":"van Kempen ZLE, Hogenboom L, Toorop AA, Steenhuis M, Stalman EW, Kummer LYL, et al. Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis. Ann Neurol. 2023;93(1):103\u20138.","journal-title":"Ann Neurol"},{"key":"1692_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211065711","author":"ZL van Kempen","year":"2021","unstructured":"van Kempen ZL, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J. Extended dosing of monoclonal antibodies in multiple sclerosis. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211065711.","journal-title":"Mult Scler"},{"key":"1692_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211028833","author":"ZY van Lierop","year":"2021","unstructured":"van Lierop ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, Strijbis EM, de Jong BA, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211028833.","journal-title":"Mult Scler"},{"key":"1692_CR17","unstructured":"Genentech USA Inc. Ocrevus. [cited 2025 September 15]. https:\/\/www.ocrevus.com\/"},{"issue":"2","key":"1692_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/bcp.13119","volume":"83","author":"JF Standing","year":"2017","unstructured":"Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol. 2017;83(2):247\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1692_CR19","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/bcp.14658","volume":"87","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Petry C, Mercier F, Gunther A, Herman A, Kappos L, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021;87(6):2511\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1692_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200056","volume":"10","author":"C Starvaggi Cucuzza","year":"2022","unstructured":"Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, et al. Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200056.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1692_CR21","unstructured":"Clinical Trials. Rituximab and ocrelizumab in serum with multiple sclerosis (ROS-MS). [cited 2025 September 15]. https:\/\/clinicaltrials.gov\/study\/NCT06663111."},{"key":"1692_CR22","unstructured":"Clinical Trials. Ocrelizumab VErsus rituximab off-label at the onset of relapsing MS disease (OVERLORD-MS). [cited 2025 September 15]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04578639."},{"key":"1692_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jmsacl.2022.07.004","volume":"25","author":"EI Hallin","year":"2022","unstructured":"Hallin EI, Traetteberg Serkland T, Myhr KM, Grytten Torkildsen O, Skrede S. Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. J Mass Spectrom Adv Clin Lab. 2022;25:53\u201360.","journal-title":"J Mass Spectrom Adv Clin Lab."},{"key":"1692_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2024.342789","volume":"1313","author":"EI Hallin","year":"2024","unstructured":"Hallin EI, Serkland TT, Bjanes TK, Skrede S. High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS\/MS. Anal Chim Acta. 2024;1313:342789.","journal-title":"Anal Chim Acta"},{"issue":"8","key":"1692_CR25","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/bcp.13970","volume":"85","author":"S Pan","year":"2019","unstructured":"Pan S, Yu H, Surti A, Cheng I, Marks SD, Brogan PA, et al. Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. Br J Clin Pharmacol. 2019;85(8):1790\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1692_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1214\/aos\/1018031103","volume":"27","author":"B Delyon","year":"1999","unstructured":"Delyon B, Lavielle V, Moulines E. Convergence of a stochastic approximation version of the EM algorithm. Ann Stat. 1999;27(1):94\u2013128.","journal-title":"Ann Stat"},{"key":"1692_CR27","volume-title":"RStudio: integrated development environment for R","author":"Posit Team","year":"2023","unstructured":"Posit Team. RStudio: integrated development environment for R. Boston: Posit Software, PBC; 2023."},{"issue":"3","key":"1692_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10928-008-9088-2","volume":"35","author":"C Dansirikul","year":"2008","unstructured":"Dansirikul C, Silber HE, Karlsson MO. Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn. 2008;35(3):269\u201383.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1692_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1692_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2):e00131.","journal-title":"Pharmacol Res Perspect"},{"key":"1692_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/9781108917407","volume-title":"Bayesian filtering and smoothing","author":"S S\u00e4rkk\u00e4","year":"2023","unstructured":"S\u00e4rkk\u00e4 S, Svensson L. Bayesian filtering and smoothing. Cambridge University Press; 2023."},{"issue":"3","key":"1692_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40263-021-00895-w","volume":"36","author":"H Yu","year":"2022","unstructured":"Yu H, Graham G, David OJ, Kahn JM, Savelieva M, Pigeolet E, et al. Population pharmacokinetic-B cell modeling for ofatumumab in patients with relapsing multiple sclerosis. CNS Drugs. 2022;36(3):283\u2013300.","journal-title":"CNS Drugs"},{"key":"1692_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106591","volume":"101","author":"M Denisa","year":"2025","unstructured":"Denisa M, Ivana K, Pavel H, Patrik M, Hana B, Pavel S, et al. Serum ocrelizumab concentrations in patients with multiple sclerosis: a cross-sectional study from routine healthcare. Mult Scler Relat Disord. 2025;101:106591.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"1692_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/FTD.0000000000000681","volume":"42","author":"M Regazzi","year":"2020","unstructured":"Regazzi M, Golay J, Molinaro M. Monoclonal antibody monitoring: clinically relevant aspects, a systematic critical review. Ther Drug Monit. 2020;42(1):45\u201356.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1692_CR35","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood-2004-09-3740","volume":"105","author":"DC Macallan","year":"2005","unstructured":"Macallan DC, Wallace DL, Zhang Y, Ghattas H, Asquith B, de Lara C, et al. B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood. 2005;105(9):3633\u201340.","journal-title":"Blood"},{"issue":"5","key":"1692_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00545-16","volume":"24","author":"PM Ladwig","year":"2017","unstructured":"Ladwig PM, Barnidge DR, Willrich MAV. Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory. Clin Vaccine Immunol. 2017;24(5):e00545-16.","journal-title":"Clin Vaccine Immunol"},{"key":"1692_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clinbiochem.2020.10.007","volume":"87","author":"A Truffot","year":"2021","unstructured":"Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V, Stanke-Labesque F, et al. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem. 2021;87:60\u20136.","journal-title":"Clin Biochem"},{"issue":"3","key":"1692_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82(3):323\u201334.","journal-title":"Drugs"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01692-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:20:01Z","timestamp":1790684401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01692-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u00d8T has received speaker honoraria from and\/or served on scientific advisory boards for Biogen, Sanofi-Aventis, Merck, Teva, Gilead and Novartis; and has participated in clinical trials organized by Biogen, Merck, Novartis, and Roche. KMM has received unrestricted research grants to his institution and scientific advisory board, and speaker honoraria from Sanofi, Novartis, and Alexion, and has participated in clinical trials organized by Biogen, Merck, Novartis, Sanofi and Roche. TTS, AKFO, SS, EIH, MH\u00d8, GON and SR declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Original data, Monolix files and R scripts to reproduce the results and figures in this manuscript are provided in Zenodo (link\n                      \n                      ).","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical studies described in this publication were approved by the regional committees for medical and health research ethics (REK approval nos. 66391, 228768) and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent to participation in the OVERLORD and ROS-MS studies.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: TTS, SS, EIH, KMM, \u00d8T, SR; Methodology: TTS, AKFO, SS, EIH, SR; Formal analysis and investigation: TTS, AKFO, EIH, SR; Writing\u2014original draft preparation: TTS, AKFO, SS, SR; Writing\u2014review and editing: TTS, AKFO, SS, EIH, KMM, \u00d8T, M\u00d8H, GON, SR; Funding acquisition: TTS, SS; Resources: TTS, SS, GON, KMM, \u00d8T; Supervision: SS, EIH, SR; Project administration: TTS, SS.","order":4,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent to participate in this study.","order":6,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ll code used in this analysis is available in the project repository at Zenodo.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}